Cytek Biosciences (CTKB) to Post Quarterly Earnings on Wednesday

Cytek Biosciences (NASDAQ:CTKB) is projected to release its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect Cytek Biosciences to post earnings of ($0.02) per share and revenue of $47.31 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Cytek Biosciences (NASDAQ:CTKB) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.07). Cytek Biosciences had a negative net margin of 36.25% and a negative return on equity of 10.07%. The firm had revenue of $44.13 million for the quarter, compared to analysts’ expectations of $44.23 million. On average, analysts expect Cytek Biosciences to post $-0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cytek Biosciences Stock Performance

CTKB stock opened at $4.22 on Monday. The company has a market cap of $544.97 million, a price-to-earnings ratio of -7.40 and a beta of 1.17. The business’s 50-day moving average is $4.30 and its two-hundred day moving average is $4.45. Cytek Biosciences has a fifty-two week low of $3.28 and a fifty-two week high of $6.18.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Stephens reduced their price target on shares of Cytek Biosciences from $5.50 to $4.75 and set an “overweight” rating for the company in a research report on Wednesday, May 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Cytek Biosciences in a report on Wednesday, June 24th. Finally, Morgan Stanley cut their target price on shares of Cytek Biosciences from $6.00 to $5.50 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $5.69.

Institutional Investors Weigh In On Cytek Biosciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC lifted its holdings in Cytek Biosciences by 394.4% during the first quarter. AQR Capital Management LLC now owns 653,277 shares of the company’s stock valued at $2,620,000 after purchasing an additional 521,135 shares in the last quarter. Jane Street Group LLC increased its stake in shares of Cytek Biosciences by 412.2% in the first quarter. Jane Street Group LLC now owns 344,169 shares of the company’s stock worth $1,380,000 after purchasing an additional 276,972 shares in the last quarter. Acadian Asset Management LLC bought a new stake in shares of Cytek Biosciences during the 1st quarter valued at $162,000. Strs Ohio bought a new stake in shares of Cytek Biosciences during the 1st quarter valued at $105,000. Finally, Creative Planning lifted its stake in shares of Cytek Biosciences by 455.4% during the 2nd quarter. Creative Planning now owns 55,677 shares of the company’s stock valued at $189,000 after buying an additional 45,652 shares in the last quarter. Institutional investors own 69.46% of the company’s stock.

Cytek Biosciences Company Profile

Cytek Biosciences is a biotechnology company specializing in innovative cell analysis solutions. The firm develops and commercializes advanced spectral flow cytometry instruments and associated reagents designed to enable high-parameter single-cell analysis. Its technology platform offers researchers and clinicians enhanced sensitivity, resolution and flexibility compared to traditional flow cytometry methods.

The company’s core product portfolio includes the Aurora and Northern Lights spectral cytometry systems, which support simultaneous detection of up to 64 fluorescence parameters.